Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17895339.
- Also identified by PMC identifier 2083216.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis.
Medical subject headings
- Meningitis, Meningococcal
- Meningococcal Infections
- Meningococcal Vaccines